Turmeric as Treatment in Epilepsy

NYU Langone Health

Status: Withdrawn

Conditions: Epilepsy; Focal Seizures; Tuberous Sclerosis; Lennox-Gastaut Syndrome; Dravet Syndrome

Treatments: Dietary Supplement: Turmeric

Study type: Interventional

Funder types: Other

Identifiers

NCT03254680

17-00750

Details and patient eligibility

About

This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures. Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months. Patients and caregivers will be asked to keep a seizure diary logging all clinical events during the course of the study. Serum comprehensive metabolic panel, complete blood count with differential, and antiseizure medication levels, will be monitored at baseline, 1.5 months, and at the end of 3 months.

Sex: All

Ages: 1 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with greater than greater than six seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures followed at NYU CEC.

Exclusion criteria

• Patients expected to have changes to any medications or supplements during study period
• exposure to any investigational agent in the month prior to study entry
• pregnant or breast feeding women, positive pregnancy test
• history of non-compliance
• known drug or alcohol dependence
• known baseline hematologic
• liver function
• renal function
• absorption
• absorption

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Turmeric Oil

Experimental group

Description:

stable dose of orally administered turmeric oil

Treatment:

Dietary Supplement: Turmeric